2165 related articles for article (PubMed ID: 8242661)
1. Phenotypic and functional profile of peripheral blood mononuclear cells isolated from melanoma patients undergoing combined immunotherapy and chemotherapy.
Eisenthal A; Skornick Y; Ron I; Zakuth V; Chaitchik S
Cancer Immunol Immunother; 1993 Nov; 37(6):367-72. PubMed ID: 8242661
[TBL] [Abstract][Full Text] [Related]
2. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
4. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
5. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
Redman BG; Flaherty L; Chou TH; Nakeff A; Pillote K; Kaplan J
J Immunother (1991); 1991 Apr; 10(2):147-51. PubMed ID: 2043595
[TBL] [Abstract][Full Text] [Related]
6. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR
Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917
[TBL] [Abstract][Full Text] [Related]
7. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
8. Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.
Yamamoto K; Tanaka R; Yoshida S; Ono K; Mori H; Taniguchi Y; Oda T; Watanabe T
J Immunother; 1999 Jan; 22(1):33-40. PubMed ID: 9924697
[TBL] [Abstract][Full Text] [Related]
9. Clonal analysis of peripheral blood lymphocytes from three patients with advanced neuroblastoma receiving recombinant interleukin-2 and interferon alpha.
Prigione I; Facchetti P; Lanino E; Garaventa A; Pistoia V
Cancer Immunol Immunother; 1993 Jul; 37(1):40-6. PubMed ID: 8513451
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C.
Arinaga S; Karimine N; Adachi M; Inoue H; Nanbara S; Asoh T; Ueo H; Akiyoshi T
Cancer Immunol Immunother; 1993 Sep; 37(4):220-6. PubMed ID: 8348560
[TBL] [Abstract][Full Text] [Related]
11. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.
Ratto GB; Costa R; Maineri P; Alloisio A; Piras MT; D'Agostino A; Tripodi G; Rivabella L; Dozin B; Bruzzi P; Melioli G
Int J Immunopathol Pharmacol; 2011; 24(4):1005-16. PubMed ID: 22230406
[TBL] [Abstract][Full Text] [Related]
12. Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients.
Joshi SS; Miller K; Jackson JD; Warkentin P; Kessinger A
Cytotherapy; 2000; 2(1):15-24. PubMed ID: 12042051
[TBL] [Abstract][Full Text] [Related]
13. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial.
Dillman RO; Oldham RK; Barth NM; Birch R; Arnold J; West WH
J Natl Cancer Inst; 1990 Aug; 82(16):1345-9. PubMed ID: 2199682
[TBL] [Abstract][Full Text] [Related]
14. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
15. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
16. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
17. Enhancing effect of pokeweed mitogen on the proliferation and the cytotoxicity of lymphokine-activated killer cells.
Kimoto Y; Tanaka T; Fujiwara A; Fujita M; Taguchi T
Jpn J Cancer Res; 1992 Jun; 83(6):631-7. PubMed ID: 1379578
[TBL] [Abstract][Full Text] [Related]
18. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.
Fortis C; Ferrero E; Besana C; Biffi M; Heltai S; Galli L; Borri A; Schoenheit A; Rugarli C
Cancer Immunol Immunother; 1990; 32(3):161-6. PubMed ID: 2289209
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
